Research ,
Develop &
Deliver

We are a leading-edge pharmaceutical company dedicated to leveraging groundbreaking research, advanced development techniques, and precision manufacturing to deliver affordable, high-quality medicines that significantly improve lives.
‍
"In honor of National Sickle Cell Awareness Month, we proudly announced the launch of SCEDAMIN™ on September 27, 2024. This pioneering treatment is set to transform the landscape of sickle cell care."
News Alert !
Press Highlights
Our Product
Innovations in Healthcare
Social Media Buzz
Future Vision

Yunigen in the News

Our innovative sickle cell anemia drug has made headlines. Discover how Yunigen’s latest pharmaceutical advancements are receiving media attention and fostering discussions on global health solutions.

‍Explore Articles

Revolutionizing Sickle Cell Treatment with SCEDAMIN™

"SCEDAMIN™ is at the forefront of sickle cell anemia treatment, offering new hope through innovative therapy. Officially launched during National Sickle Cell Awareness Month, this pioneering medication demonstrates Yunigen's commitment to advancing healthcare and improving patient outcomes worldwide."

Breaking New Ground in Sickle Cell Treatment

Yunigen recently showcased its innovative pediatric sickle cell disease treatment at the WVU Innovation Corp site, impressing Kenyan officials and global health activists. This groundbreaking approach emphasizes our commitment to accessible healthcare solutions.

Read More

Engage with Us on Instagram

Join our vibrant community on Instagram to get real-time updates and behind-the-scenes looks at how Yunigen is making a difference in the healthcare industry. Don't miss out on our interactive posts and stories!

‍Follow Us

A Vision for the Future of Healthcare

Prime Cabinet Secretary Musalia Mudavadi shares insights on the importance of addressing sickle cell disease and how innovative strategies can lead to substantial improvements in disease management and patient care.

‍Learn More

Our Story
Our Purpose
The Problem

Our Story

Discover our fomulation

Yunigen’s story is not just about its scientific achievements. It's also about its human impact—improving and saving lives through dedication and innovation.

As we expand our reach and deepen our research, we remain focused on the vision that sickle cell disease no longer dictates the quality of life or the length of life for those born with it.

Our Just Cause

"Dedicated to developing affordable and accessible healthcare solutions that address critical unmet needs in the treatment of Sickle Cell Disease globally."

Made in blender 4.0.1

What is Sickle
Cell Desease?

Sickle cell disease (SCD) is a group of inherited red blood cell disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body.

People with sickle cell disease have hemoglobin S, an abnormal type of hemoglobin, which can distort red blood cells into a sickle, or crescent, shape.

Statistics
Yunigen is dedicated to developing affordable and accessible healthcare solutions that address critical unmet needs in the treatment of Sickle Cell Disease globally.
80%
of the drugs used in Africa are imported rather than locally produced.
The price and quality of drugs significantly impact access in the region.
50% to 80%
of children affected die of Sickle Cell Disease in Africa per year.
70% of ~120 Million people
living with  Sickle Cell Disease World wide live in Africa.
~240,000 Children
are born each year of Sickle Cell Disease, live in Africa.

Our Mission

Mission
Values
Culture
This photo was made with some experimental liquids as milk, water paint and oil. I’ve made this with a friend and we had so much fun doing it. The surprise of the reactions thought the different material was both charming and changeling. I truly recommend everyone to try something like this, let’s share the different results. Have fun using this picture.by Joel Filipe
We are dedicated to developing, manufacturing, and delivering drug products that enhance people’s health and quality of life.
Empower Through Innovation: We leverage cutting-edge research and technology to develop treatments that offer new hope to those affected by Sickle Cell Disease.
Global Access: Our mission is driven by the belief that every patient, no matter where they live, should have access to affordable and effective healthcare solutions.
Sustainable Healthcare: We are dedicated to creating sustainable healthcare practices that not only benefit patients but also contribute to the health of our planet.
In the Fisher building of Detroit, deemed the most impressive commercial building ever made by Albert Kahn, the art deco interiors gleam with opulent finishes like this brass door that leads into the theater.by Erol Ahmed
Our values reflect our core beliefs, embodying the finest aspects of who we are and steering our actions in everything we do. At Yunigen, we channel our commitment, expertise, and talents, along with our passion and personal touch, to serve our patients, our customers, and our colleagues and communities.
Integrity and Ethics: We conduct our research and business practices with the highest standards of ethics and integrity, ensuring that our processes are transparent and accountable.
Collaborative Spirit: We believe in the strength of partnerships and collaborative efforts, working together with healthcare providers, communities, and governments to enhance health outcomes.
Commitment to Innovation: Continuous innovation is at the core of everything we do, from R&D to delivery, ensuring that we provide the most effective and advanced treatment options available.
a bunch of balls sitting on top of a tableby Micke Lindström
Driven by a commitment to innovation, integrity, and inclusion, our culture is built on the foundation of pushing boundaries, upholding the highest standards, and embracing diverse perspectives.
Innovation and Excellence: By fostering a culture that encourages curiosity and continuous learning, Yunigen leads the way in developing advanced treatments that set new standards for patient care and clinical outcomes.
Integrity and Ethics: Integrity is at the core of everything we do at Yunigen. We adhere to the highest ethical standards in all our research and business practices, ensuring that our work not only complies with regulatory requirements but also earns the trust and respect of the global community.
Diversity and Inclusion: Yunigen thrives on the strength of our diverse team. We are committed to creating an inclusive environment where everyone, regardless of their background, can contribute their best work. This diversity of thought and experience is crucial in helping us tackle complex health challenges and innovate without boundaries.

Our science

"Our
State-of-the-art
Manufacturing facilities


Yunigen’s follows FDA guidelines for current Good Manufacturing Practice ( cGMP ) for the manufacturing, processing and packaging of its drug products.

These regulations ensure that drugs are safe and effective , and that they contain the best ingredients , strength and standards.
Learn More

Our Process

R&D Research
Leverages the power of artificial intelligence to optimize the drug development process, reducing costs and improving efficiency.
AI innovation
AI-driven approach enables the development of customized solutions for complex therapeutic needs. Leverage the capabilities of artificial intelligence to expedite drug discovery and development.
Manufacturing
Focuses on creating high-quality and affordable pharmaceutical products to meet the unmet needs of rare diseases in emerging markets.
Research & Development
Technological Innovation
Advanced Manufacturing
Strategic Partnerships
Abstract liquid orange.by Ferhat Deniz Fors
Our Research and Development team is the driving force behind our pioneering treatments for Sickle Cell Disease, utilizing cutting-edge science to enhance patient outcomes.
Innovative Therapies Development: Focused on creating and testing innovative therapies that address unmet medical needs, particularly in underserved populations.
Clinical Trials Management: Conducting extensive, globally-distributed clinical trials to ensure the efficacy and safety of our treatments across diverse patient populations.
Pipeline Acceleration: Fast-tracking the commercialization of a robust drug pipeline to meet urgent health care needs globally.
Hi, my name is Salvatore and I have always been passionate in the world of digital art. Every day I always have many different ideas and colors. If you liked and inspired my works, and you are using them for your own projects, I would be very happy if you could support and share them. If you want, you can also make me a donation of at least $1 (PayPal: visaxslr@gmail.com ) to help me continue my work. I would be very grateful. For information and exclusive images, please contact me via DM on IG @visaxlrs. Thank youby Visax
Harnessing the power of technology, particularly through our AI Research Engine, to redefine possibilities in pharmaceutical development and patient care.
AI and Machine Learning: Utilizing AI to predict treatment outcomes, enhance drug design, and streamline clinical trials.
Data Analytics: Employing advanced data analytics to derive actionable insights from clinical data, improving research outcomes and operational efficiencies.
Digital Health Solutions: Developing digital tools and platforms that support treatment adherence and patient monitoring, enhancing the overall treatment experience.
Our state-of-the-art manufacturing facilities are equipped to produce high-quality pharmaceuticals efficiently, ensuring a stable supply of affordable medications worldwide.
cGMP Compliance: Adhering to current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy.
Scalable Production: Capabilities designed to quickly scale up production to meet global demands, particularly during health crises.
Sustainable Practices: Implementing environmentally sustainable manufacturing practices to minimize our ecological footprint while maintaining high production standards.
3D render (Blender 3.2)by Pawel Czerwinski
We believe in the power of collaboration, forming strategic partnerships with academic institutions, industry leaders, and healthcare providers to enhance innovation and accessibility of treatments.
Academic Collaboration: Working with universities to foster research and development, and to integrate the latest scientific advancements into our processes.
Industry Alliances: Forming alliances with biotech firms and pharmaceutical leaders to enhance drug development platforms and share critical knowledge.
Global Health Initiatives: Partnering with global health organizations to distribute treatments effectively, especially in regions most affected by Sickle Cell Disease.

Our Solution

Yunigen has developed the first affordable pediatric Formulation of Hydroxyurea, SCEDAMIN for the treatment of sickle cell disease. With a focus on emerging markets like Africa, we also strive to provide high-quality and affordable biotherapeutics to those in need the US.
Very affordable
for every child in africa and other emerging markets
50% to 80% Children born of Sickle cell disease die before the age of 5 in Africa
 SCEDAMIN™ will  Improvement in Patient Outcomes transform to 75% survival rate.Hydroxyurea is a prescription medication that reduces painful crises and the need for blood transfusions in children with sickle cell anemia aged 9 months and older. It may also lower the risk of complications, infections, and malaria.
Discover our Solution

Scedamin:
A Revolutionary
Fast Disintegrating Tablet

Discover "Scedamin," a cutting-edge fast disintegrating tablet that dissolves in just 30 seconds upon contact with any fluid
Learn More

Our launch

Explore our vibrant community and dedicated partnerships

Trending News

Sept 27 2024

Yunigen Inc Official Launch

Unveiling  the first affordable pediatric Formulation of hydroxyurea, SCEDAMIN for the treatment of sickle cell disease.

01

2024

Events

Yunigen official Launch Honored Guest

Overview:

Join us in welcoming our  Guest of Honor:H.E. Dr. Musalia Mudavadi, E.G.H.Prime Cabinet Secretary Cabinet Secretary for Foreign & Diaspora Affairs Republic of Kenya
‍

Source: Yunigen Launch events, 2024.
02

2024

Events

Official Product Launch

Overview:

‍Unveiling the first affordable pediatric Formulation of hydroxyurea, SCEDAMIN for the treatment of sickle cell disease.

Source:Yunigen Events Sep 2024.

03

2024  

News

Introducing our state of the art Facility

Overview :

We adhere to FDA, WHO, and cGMP guidelines in our state-of-the-art facilities, which undergo continuous improvement to fulfill international client requirements.

Source:Yunigen Events Sep 2024.

Contact Us

"Ready to

make a

difference?

Contact Yunigen and join us in revolutionizing healthcare."

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
YUNIGEN
R&D and Manufacturing Plant
‍WVU Innovation Corporation 781
Chestnut Ridge Road,
Morgantown, WV 26505 USA

‍Yunigen innovation Hub
‍960 E Green St, Pasadena,
California 91106 USA.

Yunigen Kenya
Nairobi Kenya

Call
+818 433 2715

‍
Home
© Yunigen powered by Webflow